Preference of inhalants over pills/injections among pulmonary tuberculosis patients in Western India: A cross-sectional study

Ahuja, Nirmal; Sznajder, Kristin K.; Patil, Rajendra; Shaikh, Bushra

doi:10.1016/j.jctube.2021.100234

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The direct administration of drugs to the lungs is a promising way to address these challenges. The preference for inhaled oral or intravenous formulations in patients is associated with their clinical characteristics, and inhalation may be a more acceptable method in this patient group [ 329 ]. Several types of dosage forms of anti-tuberculosis drugs have been studied.…”

Section: Application Of Pulmonary Drug Deliverymentioning

confidence: 99%

Pulmonary inhalation for disease treatment: Basic research and clinical translations

Wang,

Yang

et al. 2024

Materials Today Bio

View full text Add to dashboard Cite

Section: Application Of Pulmonary Drug Deliverymentioning

confidence: 99%

Pulmonary inhalation for disease treatment: Basic research and clinical translations

Wang,

Yang

et al. 2024

Materials Today Bio

View full text Add to dashboard Cite

“…The copyright holder for this preprint this version posted November 16, 2023. ; https://doi.org/10.1101/2023.11. 16.567434 doi: bioRxiv preprint One of the limitations of using 1599 as injectable is a potential risk for poor patient compliance (24) and direct administration of aerosolized antibiotics to the lungs has been studied for decades as an alternative to systemic drug administration via injection. Aerosolized administration of 1599 has been tested in preclinical in vivo studies using liquid formulation of the drug.…”

Section: Introductionmentioning

confidence: 99%

A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides

Ali,

Dutt,

MacNeill

et al. 2023

Preprint

View full text Add to dashboard Cite

The Nix-TB clinical trial evaluated a new 6-month regimen containing three-oral-drugs; bedaquiline (B), pretomanid (Pa) and linezolid (L) (BPaL regimen) for treatment of tuberculosis (TB). This regimen achieved remarkable results as almost 90% of the multidrug resistant (MDR) or extensively drug resistant (XDR) TB participants were cured but many patients also developed severe adverse effects (AEs). The AEs were associated with the long-term administration of the protein synthesis inhibitor linezolid. Spectinamide 1599 (S) is also a protein synthesis inhibitor ofMycobacterium tuberculosiswith an excellent safety profile but which lacks oral bioavailability. Here we hypothesize that inhaled spectinamide 1599, combined with BPa ––BPaS regimen––has similar efficacy to that of BPaL regimen while simultaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the Balb/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effect in both TB murine models. However, treatment with BPaL resulted in significant weight loss and the complete blood count suggested development of anemia. These effects were not similarly observed in mice treated with BPaS. BPaL treatment also decreased myeloid to erythroid ratio and increased concentration of proinflammatory cytokines in bone marrow compared to mice receiving BPaS regimen. During therapy both regimens improved the lung lesion burden, reduced neutrophil and cytotoxic T cells counts while increased the number of B and helper and regulatory T cells. These combined data suggest that inhaled spectinamide 1599 combined with BPa is an effective TB regimen that avoids L-associated AEs.IMPORTANCETuberculosis (TB) is an airborne infectious disease that spreads via aerosols containingMycobacterium tuberculosis(Mtb), the causative agent of TB. TB can be cured by administration of 3-4 drugs for 6-9 months but there are limited treatment options for patients infected with multidrug (MDR) and extensively resistant (XDR) strains of Mtb. BPaL is a new all-oral combination of drugs consisting of Bedaquiline (B), Pretomanid (Pa) and Linezolid (L). This regimen was able to cure ∼90% of MDR and XDR TB patients in clinical trials but many patients developed severe adverse effects (AEs) associated to the long-term administration of linezolid. We evaluated a new regimen in which Linezolid in the BPaL regimen was replaced with inhaled spectinamide 1599. In the current study, we demonstrate that 4-weeks of treatment with inhaled spectinamide 1599 in combination with Bedaquiline and Pretomanid has equivalent efficacy to the BPaL drug combination and avoids the L-associated-AEs.

show abstract

‘If not for this support, I would have left the treatment!': Qualitative study exploring the role of social support on medication adherence among pulmonary tuberculosis patients in Western India

Ahuja

Kuzmik

Sznajder

et al. 2021

Global Public Health

View full text Add to dashboard Cite

Preference of inhalants over pills/injections among pulmonary tuberculosis patients in Western India: A cross-sectional study

Cited by 3 publications

References 30 publications

Pulmonary inhalation for disease treatment: Basic research and clinical translations

Pulmonary inhalation for disease treatment: Basic research and clinical translations

A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides

‘If not for this support, I would have left the treatment!': Qualitative study exploring the role of social support on medication adherence among pulmonary tuberculosis patients in Western India

Contact Info

Product

Resources

About